Company Overview
Company Type: Public Company
Website: www.stagezerolifesciences.com
Number of Employees: 40
Ticker: SZLS (TSX)
Year Founded: -


Business Description
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
4.1
Market Capitalization
6.8
TEV/Total Revenue
2.1x
EBITDA
(6.8)
Total Enterprise Value
8.6
TEV/EBITDA
NM
EBIT
(7.1)
Cash & ST Invst.
0.1
P/Diluted EPS Before Extra
NM
Net Income
(16.1)
Total Debt
2.0
Price/Tang BV
NM
Total Assets
1.1
Total Debt/EBITDA
NM


Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023

Key Professionals
Name
Title
Howard-Tripp, James R.
Executive Chairman & CEO
Liew, Choong-Chin 
Co-Founder
Whitehead, Warren 
Chief Accountant

Key Board Members
Name
Title
Howard-Tripp, James R.
Executive Chairman & CEO
Glorikian, Harry A.
Independent Director
Levin, Bernard 
Chairman of Colorectal Cancer Clinical Advisory Board
MacRae, Garth A. C.
Independent Director
Baker, Jeffrey 
Member of Colorectal Cancer Clinical Advisory Board
Bikman, Benjamin 
Member of Scientific Advisory Board
Boyd, Barry 
Member of Scientific Advisory Board
Cohen, Lawrence
Member of Colorectal Cancer Clinical Advisory Board
Fung, Jason 
Member of Scientific Advisory Board
Jeejeebhoy, Khursheed 
Member of Colorectal Cancer Clinical Advisory Board
Lieberman, David A.
Member of Colorectal Cancer Clinical Advisory Board
Riggs, Rory Balfour
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
70 East Beaver Creek Road Unit 30 | Richmond Hill, ON | L4B 3B2 | Canada

Current and Pending Investors
1985275 Ontario Inc., Alumina Partners LLC, Global Emerging Markets, Lind Asset Management XI, LLC, Milost Global Inc., Mosaix Ventures, PowerOne Capital Markets Limited, Investment Arm, Scientia Ventures

Prior Investors
AWM Investment Company Inc, Pinetree Capital Ltd. (TSX:PNP)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.06
Market Cap (mm)
6.8
Open
 0.06
Shares Out. (mm)
123.5
Previous Close
 0.06
Float %
77.3%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.06/ 0.06
Diluted EPS Excl. Extra Items
(0.15)
52 wk High/Low
 0.15/ 0.05
P/Diluted EPS Before Extra
NM
Volume (mm)
0.04
Avg 3M Dly Vlm (mm)
0.03
Beta 5Y
0.74


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
TSX:SZLS - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
All Assets of Health Clinics Limited and Health Clinics USA Corp.
As of September 2, 2021, All Assets of Health Clinics Limited and Health Clinics USA Corp. were acquired by StageZero Life Sciences Ltd.. All Assets of Health Clinics Limited and Health Clinics USA Corp. comprises oncology treatment business. The assets are located in the United States.

United States and Canada
Health Care Services
-
-
-
Innovative Diagnostic Laboratory, LLP
 Innovative Diagnostic Laboratory, LLP operates a clinical reference lab that specializes in personalized blood-based testing to help find, understand, and address cancer risk in patient populations. The company offers risk assessment blood tests for lung, colon, and prostate cancer types. Its solutions include ColonSentry, a blood test that measures the expression of seven gene biomarkers (signatures) in the blood that are early warning signs of colon cancer; EarlyCDT-Lung, a blood test that aids in risk assessment and the early detection of lung cancer in high-risk, asymptomatic patients; and Prostate Health Index, a blood test for detecting prostate cancer. The company also licenses and commercializes an array of DNA, RNA, protein, and autoantibody blood-based cancer diagnostic tests to address early detection of various major types of cancer; and offers health risk assessment administration and chronic disease management programs. In addition, it offers MyCancerRisk, a program to help physicians identify a patient’s personal cancer risk. The company was founded in 2012 and is based in Richmond, Virginia. As of March 15, 2016, Innovative Diagnostic Laboratory, LLP operates as a subsidiary of  GeneNews Limited.

United States and Canada
Health Care Services
-
-
-
Lewis Brook Resources Ltd.
As of May 31, 2000, Lewis Brook Resources Ltd. was acquired by ChondroGene Inc., in a reverse merger transaction. 

United States and Canada
Diversified Metals and Mining
-
-
-
Clinics Operations Limited (Pending)

Europe
-
-
-
-
GeneNews (USA), Inc

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-18-2022
Aug-18-2022
Private Placement
Target
StageZero Life Sciences Ltd. (TSX:SZLS)


0.14
Feb-28-2022
Mar-03-2022
Private Placement
Target
StageZero Life Sciences Ltd. (TSX:SZLS)


1.47
Nov-23-2021
Nov-26-2021
Private Placement
Target
StageZero Life Sciences Ltd. (TSX:SZLS)


3.28
Apr-01-2021
Sep-02-2021
Merger/Acquisition
Buyer
All Assets of Health Clinics Limited and Health Clinics USA Corp.
StageZero Life Sciences Ltd. (TSX:SZLS)
Health Clinics Limited,Health Clinics USA Corp.
7.92
Oct-19-2020
Dec-4-2020
Public Offering
Target
StageZero Life Sciences Ltd. (TSX:SZLS)


5.63
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-15-2023
Earnings Calls
StageZero Life Sciences Ltd., Q2 2023 Earnings Call, Aug 15, 2023
Jun-07-2023
Shareholder/Analyst Calls
StageZero Life Sciences Ltd. - Shareholder/Analyst Call
Jun-07-2023
Annual General Meeting
StageZero Life Sciences Ltd., Annual General Meeting, Jun 07, 2023
May-16-2023
Earnings Calls
StageZero Life Sciences Ltd., Q1 2023 Earnings Call, May 16, 2023
Apr-03-2023
Earnings Calls
StageZero Life Sciences Ltd., Q4 2022 Earnings Call, Apr 03, 2023

M&A Advisors
Torys LLP


Advisors
Most Recent Auditor
SRCO Professional Corporation
M&A Advisors
Torys LLP
Private Placement Advisors
All Group Financial Services Inc., Canaccord Genuity Corp., Direct Markets Holdings Corporation, Fasken Martineau DuMoulin LLP, H.C. Wainwright & Co., LLC, Loewen Ondaatje McCutcheon Limited, Investment Banking Arm, Paradigm Capital Inc., PowerOne Capital Markets Limited, Stifel Nicolaus Canada Inc., Troutman Pepper Hamilton Sanders LLP, WeirFoulds LLP
Public Offering Advisors
BDO Canada LLP, Troutman Pepper Hamilton Sanders LLP, WeirFoulds LLP


Most Recent Auditor
SRCO Professional Corporation


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:44 AM
SZLS
StageZero Life Sciences Ltd 2023_10_05
Reports
14
New Constructs, LLC

Sep 29, 2023 08:16 PM
SZLS
GEN: Forensic Stock Earnings & Valuation
Reports
6
GlobalData

Sep 26, 2023 05:09 AM
SZLS
StageZero Life Sciences Ltd (SZLS.TSE) - Medical Equipment - Deals and Alliances Profile
Reports
69
MarketLine

Sep 14, 2023 06:01 AM
SZLS
GeneNews Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
304
GlobalData

Sep 08, 2023 12:21 AM
SZLS
StageZero Life Sciences Ltd (SZLS.TSE) - Financial Analysis Review
Reports
195
S&P Global Compustat

Sep 07, 2023 03:27 AM
SZLS
StageZero Life Sciences Ltd 2023_09_07
Reports
14
ValuEngine, Inc.

Sep 01, 2023 03:42 AM
SZLS
ValuEngine - Toronto Quantitative Stock Report for SZLS
Reports
5
S&P Global Compustat

Jul 06, 2023 03:01 AM
SZLS
StageZero Life Sciences Ltd 2023_07_06
Reports
14
GlobalData

Jun 14, 2023 02:45 AM
SZLS
StageZero Life Sciences Ltd (SZLS.TSE) - Financial Analysis Review
Reports
195
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jun 12, 2023 06:00 PM
SZLS
Rating Update for StageZero Life Sciences Ltd
EPS Estimates*
3


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Health Clinics Limited

15,000,000

12.14

0.8

Apr-28-2023


Riggs M.B.A., MBA, Rory Balfour

12,541,406

10.15

0.7

Jun-08-2023


Howard-Tripp, James R.

232,759

0.19

0.0

Apr-28-2023


B.E.S.T. Investment Counsel Limited

151,388

0.12

0.0

Feb-28-2023


MacRae CA, Garth A. C.

147,086

0.12

0.0

Apr-28-2023


Glorikian MBA, Harry A.

107,154

0.09

0.0

Apr-28-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Riggs M.B.A., MBA, Rory Balfour
12,541,406
10,745,077
Health Clinics Limited
15,000,000
2,600,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Howard-Tripp, James R.
232,759
(28,300)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Aristotle, BreastSentry, ColonSentry, COVID-19 Tests, Sphingotest pro-ENK, Sphingotest pro-NT


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Aug-14-2023
Jun-30-2023
StageZero Life Sciences Ltd. (TSX:SZLS)
SEDAR
Interim Financial Statements
501 KB
Jun-20-2023
-
StageZero Life Sciences Ltd. (TSX:SZLS)
SEDAR
News Releases
34 KB
Jun-07-2023
-
StageZero Life Sciences Ltd. (TSX:SZLS)
SEDAR
News Releases
29 KB
Jun-05-2023
-
StageZero Life Sciences Ltd. (TSX:SZLS)
SEDAR
News Releases
24 KB
May-16-2023
-
StageZero Life Sciences Ltd. (TSX:SZLS)
SEDAR
News Releases
33 KB
May-15-2023
-
StageZero Life Sciences Ltd. (TSX:SZLS)
SEDAR
News Releases
27 KB
May-15-2023
Mar-31-2023
StageZero Life Sciences Ltd. (TSX:SZLS)
SEDAR
Interim Financial Statements
475 KB
May-08-2023
-
StageZero Life Sciences Ltd. (TSX:SZLS)
SEDAR
Management Proxy Materials
132 KB
May-05-2023
-
StageZero Life Sciences Ltd. (TSX:SZLS)
SEDAR
Management Proxy Materials
450 KB
May-05-2023
-
StageZero Life Sciences Ltd. (TSX:SZLS)
SEDAR
Management Proxy Materials
598 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Riggs M.B.A., MBA, Rory Balfour (Independent Director)
Jun-08-2023
Common Shares
10,745,077
770,382
Derivative Exercise and Retained Stock
598.17
Multiple
Riggs M.B.A., MBA, Rory Balfour (Independent Director)
Jun-08-2023
Common Shares
(10,745,077)
0
Derivative Exercise and Sale
-
Multiple
-
Jun-08-2023
Common Shares
10,745,077
770,382
Derivative Exercise
-
Exchange Announcement
-
Jun-08-2023
Common Shares
(10,745,077)
(770,382)
Sale
-
Exchange Announcement
Howard-Tripp, James R. (Executive Chairman & CEO)
Aug-19-2021
Common Shares
28,300
10,440
Open Market Acquisition
12.16
Multiple
MacRae CA, Garth A. C. (Independent Director)
Dec-22-2020
Common Shares
36,120
9,174
Derivative Exercise and Retained Stock
32.55
Exchange Announcement
Howard-Tripp, James R. (Executive Chairman & CEO)
Dec-22-2020
Common Shares
100,000
25,398
Derivative Exercise and Retained Stock
75.32
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Howard-Tripp, James R.
Executive Chairman & CEO
1-855-420-7140x1
-
jht@stagezerols.com
Glorikian, Harry A.
Independent Director
-
-

Levin, Bernard 
Chairman of Colorectal Cancer Clinical Advisory Board
-
-

MacRae, Garth A. C.
Independent Director
-
-

Baker, Jeffrey 
Member of Colorectal Cancer Clinical Advisory Board
-
-

Bikman, Benjamin 
Member of Scientific Advisory Board
-
-

Boyd, Barry 
Member of Scientific Advisory Board
-
-

Cohen, Lawrence
Member of Colorectal Cancer Clinical Advisory Board
-
-
-
Fung, Jason 
Member of Scientific Advisory Board
-
-

Jeejeebhoy, Khursheed 
Member of Colorectal Cancer Clinical Advisory Board
-
-

Lieberman, David A.
Member of Colorectal Cancer Clinical Advisory Board
-
-

Riggs, Rory Balfour
Independent Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Howard-Tripp, James R.
Executive Chairman & CEO
1-855-420-7140x1
-
jht@stagezerols.com
Liew, Choong-Chin 
Co-Founder
-
-

Whitehead, Warren 
Chief Accountant
-
-
warren.whitehead@amorfix.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
